Overview

Colorectal Cancer (CRC) Cetuximab Elderly Frail

Status:
Terminated

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

OBJECTIVE: The principal objective of the trial is to evaluate whether the addition of cetuximab associated with 5-fluorouracil in elderly patients with KRAS wild type advanced colorectal cancer (CRC) prolongs Progression Free Survival, compared with 5-fluorouracil alone.

Phase:

Phase 2

Details

Lead Sponsor:

European Organisation for Research and Treatment of Cancer - EORTC

Collaborators:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Cetuximab
Fluorouracil
Leucovorin